On November 13, 2025, the 14th China Innovation and Entrepreneurship Competition Biomedical National Competition successfully concluded in Haikou, Hainan. Since its launch, this competition has attracted nearly30000 enterprisesRegistration, after layers of selection by competition area, finally228 projectsNominated for the national competition, only20 projectsNominated for the finals.With its core technological advantages and industrialization potential, Xijian Technology has successfully advanced to the semi-finals and finals, and won the "Excellent Enterprise Award" of this competition.

The China Innovation and Entrepreneurship Competition is one of the longest, largest, and most influential events in China. Since its establishment in 2012, it has been held for fourteen consecutive sessions. The competition adheres to the principle of "government guidance, public welfare support, and market assistance", and has attracted nearly 300000 participating companies and teams. The winning companies and teams have received a large amount of government support, market financing, and other services. The competition integrates industry docking, policy promotion, professional training, and competitive selection, focusing on cutting-edge directions such as innovative medicine, medical devices, and medical digitization. Its aim is to discover and cultivate a group of innovative forces with disruptive potential.

This competition is guided by the Torch High tech Industry Development Center of the Ministry of Industry and Information Technology, supported by the Hainan Provincial Department of Industry and Information Technology, the Hainan Provincial Department of Science and Technology, and the Haikou Municipal People's Government, and organized by the Haikou National High tech Zone. It covers multiple sub tracks such as biotechnology, medical equipment, high-end diagnostic and treatment equipment, and smart healthcare.This competition has a grand scale, standardized organization, and high industry participation, gathering experts and scholars from research institutions, universities, medical institutions, and industrial capital across the country. The evaluation standards are strictly professional, and the competition is regarded by the industry as the highest level, largest scale, and most influential national level scientific and technological innovation competition in the field of biomedicine in China,It is not only an arena for innovative achievements, but also a highland for the gathering of industrial resources.

Xijian TechnologyQuantitative testing platform technology for soft tissue mechanicsParticipating in the competition, the project has received attention from the judging experts since the preliminary stage, demonstrating good advantages in terms of technological innovation, clinical application value, industrialization path, and team execution ability. In the semi-finals and finals, Xijian Technology faces mostly mature companies in the industry with more solid capital and market foundations.Despite fierce competition, Xijian Technology still received recognition from the judges for its clear product logic, solid data foundation, and feasible business model.

This selection emphasizes the practical industry significance and future growth potential of the project, which plays a positive role in promoting the subsequent resource docking, industry landing, and brand building of the enterprise. The award of Xijian Technology marks the company's professional recognition in the industry for its technological system construction, product application scenario expansion, and commercialization capabilities.

This award is not only a milestone achievement, but also a new starting point. Xijian Technology will continue to increase research and development investment, strengthen product validation and clinical pilot cooperation, and accelerate the landing of technological achievements on the application side. In the future, Xijian Technology will deepen its collaborative cooperation with research institutes, medical institutions, and industrial parks, further enhance its technological maturity and large-scale deployment capabilities, and contribute to the innovative development of the biopharmaceutical industry.